Zobrazeno 1 - 10
of 870
pro vyhledávání: '"immuno-PET"'
Autor:
Kyung-Ho Jung, Mina Kim, Hye Jin Jung, Hyun Jung Koo, Jung-Lim Kim, Hyunjong Lee, Kyung-Han Lee
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract CD73 is a cell-surface ectoenzyme that hydrolyzes the conversion of extracellular adenosine monophosphate to adenosine, which in turn can promote resistance to immune checkpoint blockade therapy. Immune response may therefore be improved by
Externí odkaz:
https://doaj.org/article/fdcbb2eca6e449df9bb4d885e1e5ca64
Autor:
Valentina Albanese, Chiara Roccatello, Salvatore Pacifico, Remo Guerrini, Delia Preti, Silvia Gentili, Matteo Tegoni, Maurizio Remelli, Denise Bellotti, Jonathan Amico, Giancarlo Gorgoni, Emiliano Cazzola
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-25 (2024)
Abstract Background Positron emission tomography (PET) is a highly sensitive method that provides fine resolution images, useful in the field of clinical diagnostics. In this context, Zirconium-89 (89Zr)-based imaging agents have represented a great
Externí odkaz:
https://doaj.org/article/8b015e677f7b462d9caf7d52aac9d576
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-21 (2024)
Abstract Background During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in preclinical and clinical drug development and patient selection, primarily due to its advantageous p
Externí odkaz:
https://doaj.org/article/bc06d18625874015acb5db58734cf373
Autor:
Xingguo Hou, Song Liu, Ziqing Zeng, Zilei Wang, Jin Ding, Yan Chen, Xiangyu Gao, Jianghua Wang, Guanxi Xiao, Baiyong Li, Hua Zhu, Zhi Yang
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 175, Iss , Pp 116669- (2024)
Background: The lack of an efficient way to screen patients who are responsive to immunotherapy challenges PD1/CTLA4-targeting cancer treatment. Immunotherapeutic efficacy cannot be clearly determined by peripheral blood analyses, tissue gene markers
Externí odkaz:
https://doaj.org/article/13404cc6508345a7bca0ac26b12a45c3
Autor:
Ander Puyalto, María Rodríguez-Remírez, Inés López, Fabiola Iribarren, Jon Ander Simón, Marga Ecay, María Collantes, Anna Vilalta-Lacarra, Alejandro Francisco-Cruz, Jose Luis Solórzano, Sergio Sandiego, Iván Peñuelas, Alfonso Calvo, Daniel Ajona, Ignacio Gil-Bazo
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundHarnessing the anti-tumor immune system response by targeting the program cell death protein (PD-1) and program cell death ligand protein (PD-L1) axis has been a major breakthrough in non-small cell lung cancer (NSCLC) therapy. Nonetheless,
Externí odkaz:
https://doaj.org/article/6925a7c87bd849e1b214135adddcbb6a
Autor:
Yinfei Chen, Shiyu Zhu, Jiayu Fu, Jianguo Lin, Yan Sun, Gaochao Lv, Minhao Xie, Tao Xu, Ling Qiu
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 12, Iss 6, Pp 869-878 (2022)
Despite advances in immunotherapy for the treatment of cancers, not all patients can benefit from programmed cell death ligand 1 (PD-L1) immune checkpoint blockade therapy. Anti-PD-L1 therapeutic effects reportedly correlate with the PD-L1 expression
Externí odkaz:
https://doaj.org/article/973b9fbccc764f1aa05203155e8d8c55
Autor:
Aditi Mulgaonkar, Durga Udayakumar, Yaxing Yang, Shelby Harris, Orhan K. Öz, Praveen Ramakrishnan Geethakumari, Xiankai Sun
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Chimeric antigen receptor (CAR) T-cell therapies have evolved as breakthrough treatment options for the management of hematological malignancies and are also being developed as therapeutics for solid tumors. However, despite the impressive patient re
Externí odkaz:
https://doaj.org/article/f1f1996dcbf2454e873de44322b482f4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ashutosh Wechalekar, Gunnar Antoni, Wasfi Al Azzam, Mats Bergström, Swethajit Biswas, Chao Chen, Joseph Cheriyan, Matthew Cleveland, Louise Cookson, Paul Galette, Robert L. Janiczek, Raymond Y. Kwong, Mary Ann Lukas, Helen Millns, Duncan Richards, Ian Schneider, Scott D. Solomon, Jens Sörensen, James Storey, Douglas Thompson, Guus van Dongen, Danielle J. Vugts, Anders Wall, Gerhard Wikström, Rodney H. Falk
Publikováno v:
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-16 (2022)
Abstract Background In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloi
Externí odkaz:
https://doaj.org/article/a733adacf3434f19a23e0e826ad2a704
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionPositron emission tomography (PET) using radiolabeled Abs as imaging tracer is called immuno-PET. Immuno-PET can verify therapeutic Ab delivery and can noninvasively quantify global levels of target expression in tumors of living subjects
Externí odkaz:
https://doaj.org/article/cf0f760615274d70b3910abd4cd4907e